Sec Form 4 Filing - SHERMAN STEVEN @ EKSO BIONICS HOLDINGS, INC. - 2022-11-21

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
SHERMAN STEVEN
2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [ EKSO]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
CEO & Chairman
(Last) (First) (Middle)
C/O EKSO BIONICS HOLDINGS, INC., 101 GLACIER POINT, SUITE A
3. Date of Earliest Transaction (MM/DD/YY)
11/21/2022
(Street)
SAN RAFAEL, CA94901
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/21/2022 M 15,599 A $ 0 713,829 D
Common Stock 11/21/2022 S 5,787( 1 ) D $ 1.2636( 2 ) 708,042 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units ( 3 ) 11/21/2022 M 15,599 ( 4 ) ( 4 ) Common Stock 15,599 $ 0 31,199 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
SHERMAN STEVEN
C/O EKSO BIONICS HOLDINGS, INC.
101 GLACIER POINT, SUITE A
SAN RAFAEL, CA94901
X CEO & Chairman
Signatures
/s/ Jerome Wong, as Attorney-in-Fact 11/23/2022
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Represents shares sold by the Reporting Person on November 22, 2022 to cover tax withholding obligations incurred upon the vesting and settlement of the tenth installment of a restricted stock award originally reported by the Reporting Person in Form 4 filed with the Commission on March 10, 2022
( 2 )The sale price represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $1.26 to $1.27, inclusive. The Company can provide the full information regarding the number of shares sold at each separate price upon further request.
( 3 )The restricted stock units ("RSUs") were granted on March 8, 2022 in accordance with the terms of an Executive Employment Agreement entered into between the Reporting Person and the Company on January 21, 2022 (the "Effective Date").
( 4 )The RSUs vest in twelve equal installments on the first twelve monthly anniversaries of the Effective Date, starting February 21, 2022, such that the RSUs will be fully vested as of January 21, 2023. The tenth installment of RSUs vested on November 21, 2022 and were delivered to the Reporting Person upon settlement.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.